Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria
Kassoum Kayentao, Aïssata Ongoïba, Anne C Preston, Sara A. Healy, Zonghui Hu, Jeff Skinner, Safiatou Doumbo, Jing Wang, Hamidou Cisse, Didier Doumtabé, Abdrahamane Traoré, Hamadi Traore, Adama Djiguiba, Shanping Li, Mary Peterson, Shinyi Telscher, Azza H. Idris, William C. Adams, Adrian B. McDermott, Sandeep Narpala, Bob C. Lin, Leonid Serebryannyy, Somia P. Hickman, Andrew McDougal, Sandra Vazquez, M.A. REIBER, Judy Stein, Jason G. Gall, Kevin Carlton, Philipp Schwabl, Siriman Traoré, Mamadou Keïta, Amatigué Zéguimé, Adama Ouattara, M’Bouye Doucoure, Amagana Dolo, Sean C. Murphy, Daniel E. Neafsey, Sílvia Portugal, Abdoulaye Djimdé, Boubacar Traoré, Robert A. Seder, Peter D. Crompton
Abstract
BACKGROUND: infection in a region where this organism is endemic is unclear. METHODS: infection, as detected on blood smear performed at least every 2 weeks for 24 weeks. A secondary efficacy end point was the first episode of clinical malaria, as assessed in a time-to-event analysis. RESULTS: infection, as compared with placebo, was 66% (adjusted confidence interval [95% CI], 45 to 79) with the 150-mg dose and 70% (adjusted 95% CI, 50 to 82) with the 300-mg dose (P<0.001 for both comparisons). Efficacy against clinical malaria was 67% (adjusted 95% CI, 39 to 82) with the 150-mg dose and 77% (adjusted 95% CI, 55 to 89) with the 300-mg dose (P<0.001 for both comparisons). CONCLUSIONS: infection and clinical malaria over a period of 6 months. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT05304611.).